"The results of our study show promise that a treatment option, while not a cure for retinitis pigmentosa, could be available in the future," said Dr. Walter-G. Wrobel, chairman and founder, Okuvision GmbH. "While much is still unknown about EST technology, the results of the study are a great step toward determining efficacy of this treatment and we look forward to conducting further studies to potentially reach out to those who are hopeful in delaying the effects of retinitis pigmentosa."
The study findings were also reported online on April 5, 2011 in Investigative Ophthalmology & Visual Science, the official journal of ARVO (www.iovs.org, A.Schatz et.al., IOVS Papers in Press. Published on April 5, 2011 as Manuscript iovs.10-6932).
Ad Statistics
Times Displayed: 50049
Times Visited: 1414 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
The Okuvision therapy device is not for sale in the United States.
About Okuvision GmbH
Founded by the leaders of Retina Implant AG in 2007, Okuvision GmbH is an innovator in the field of electrical stimulation therapy (EST) for patients with early and intermediate stage retinitis pigmentosa. Building on the lessons learned through the use of Retina Implant's subretinal implant technology, Okuvision was founded with the goal of testing and developing a treatment option aimed at delaying the effects of retinitis pigmentosa. Okuvision's first study began in 2007 and treated 24 patients over a period of six weeks. To learn more, please visit: www.okuvision.de.
Back to HCB News
